InflaRx (IFRX) Return on Capital Employed (2017 - 2026)
InflaRx's (IFRX) quarterly Return on Capital Employed came in at 14.9% in Q1 2026, up 1623.0% year-on-year from 0.86% in Q1 2025, and up 349.88% quarter-over-quarter from 3.31% in Q4 2025.
InflaRx (IFRX) Return on Capital Employed (2017 - 2026) Analysis & Trends
InflaRx has disclosed Return on Capital Employed across 10 years of filings, most recently posting 14.9% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 14.9%, up 1623.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.9% (up 1623.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
- Return on Capital Employed came in at 14.9% for Q1 2026 at InflaRx, up from 3.31% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.9% in Q1 2026 to a low of 78.01% in Q3 2024.
- The 5-year median for Return on Capital Employed is 23.41% (2023), against an average of 22.93%.
- Across the five-year window, Return on Capital Employed plunged 2000000000 bps in 2022 and jumped 8992 bps in 2025, its largest moves.
- InflaRx's Return on Capital Employed stood at 27.05% in 2022, then decreased by 17 bps to 31.78% in 2023, then surged by 96 bps to 1.16% in 2024, then jumped by 385 bps to 3.31% in 2025, then soared by 350 bps to 14.9% in 2026.
- The last three Return on Capital Employed figures came in at 14.9% (Q1 2026), 3.31% (Q4 2025), and 11.9% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 14.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.90% |
| Dec 31, 2025 | 3.31% |
| Sep 30, 2025 | 11.90% |
| Jun 30, 2025 | 1.51% |
| Mar 31, 2025 | -1.32% |
| Dec 31, 2024 | -1.16% |
| Sep 30, 2024 | -78.01% |
| Jun 30, 2024 | -58.21% |
| Mar 31, 2024 | -46.03% |
| Dec 31, 2023 | -31.78% |
| Sep 30, 2023 | -23.41% |
| Jun 30, 2023 | -16.81% |
| Mar 31, 2023 | -9.88% |
| Dec 31, 2022 | -27.05% |
| Sep 30, 2022 | -30.70% |
| Jun 30, 2022 | -41.97% |
| Mar 31, 2022 | -55.18% |
| Dec 31, 2021 | -44.52% |
| Sep 30, 2021 | 21,588,683.20% |
| Jun 30, 2021 | 19,456,381.62% |